Marker Therapeutics (FRA:GX1) Price-to-Operating-Cash-Flow : (As of May. 19, 2024)

View and export this data going back to . Start your Free Trial

What is Marker Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-05-19), Marker Therapeutics's share price is €3.94. Marker Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.74. Hence, Marker Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Marker Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

FRA:GX1's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 26.69
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Marker Therapeutics's Cash Flow from Operations per share for the three months ended in Dec. 2023 was €-0.24. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.74.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 24.00% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 20.10% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 24.60% per year.

During the past 13 years, Marker Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 66.60% per year. The lowest was 7.00% per year. And the median was 23.00% per year.

Marker Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Marker Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marker Therapeutics Price-to-Operating-Cash-Flow Chart

Marker Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Marker Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Marker Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Marker Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marker Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marker Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Marker Therapeutics's Price-to-Operating-Cash-Flow falls into.

Marker Therapeutics Price-to-Operating-Cash-Flow Calculation

Marker Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	3.94	/	-1.735
	=

Marker Therapeutics's Share Price of today is €3.94.
Marker Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.74.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Marker Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Marker Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Marker Therapeutics (FRA:GX1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (FRA:GX1) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

MRKR:USA

Address

4551 Kennedy Commerce Drive, Houston, TX, USA, 77032

Website

http://www.markertherapeutics.com

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Marker Therapeutics (FRA:GX1) Headlines

No Headlines